Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Takashi Ikeda, Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Toshio Takagi, Junpei Iizuka, Yasunobu Hashimoto, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
Topics & Concepts
NivolumabMedicineIpilimumabRenal cell carcinomaAdverse effectOncologyInternal medicineImmune systemKidney cancerCarcinomaImmunotherapyCancerImmunologyCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentFerroptosis and cancer prognosis